Companies /Healthcare

GeneDx Holdings Corp - Class A

NASDAQ: WGS Diagnostics & Research
$51.96
▲ $4.67 (+9.88%) today
Markets closed · 12:46am ET

WGS at a Glance

Valuation
Market cap
$1.6B
Profitability
Revenue (TTM)
$460.8M
Profit margin
-24.1%
EPS (TTM)
$-3.76
Price
52-week range
$32 – $171
Street target
$82.00

Headquartered in Stamford, CT Fiscal year ends December NASDAQ: WGS genedx.com

About GeneDx

GeneDx Holdings Corp. is a genomics diagnostics company focused on rare disease diagnosis.

Its core products are its exome and genome sequencing tests, ExomeDx and GenomeDx. These are offered as standard, rapid and ultrarapid tests and in a prenatal version, and have been granted FDA Breakthrough Device designation. They are powered by GeneDx Infinity, a rare disease genomic dataset the company says spans more than 2.5 million genetic tests and about 1 million exomes and genomes.

The company earns most of its revenue from diagnostic tests reimbursed by commercial payers and Medicaid. Smaller revenue lines include:
- Legacy targeted panel tests.
- Data information services for biopharma, used for drug discovery, clinical trial enablement and real-world evidence.
- Software and interpretation services, including capabilities from its Fabric Genomics acquisition.

GeneDx's foundational customers are geneticists and pediatric specialists. It is expanding into NICUs, general pediatricians, prenatal care, adult specialists (starting with neurologists) and international markets. It is also developing genomic newborn screening (through the GUARDIAN and BRIDGES-NBS studies), new direct-access online channels, and biopharma sponsored testing programs. Updated

WGS Coverage

Frequently Asked Questions

What does GeneDx do?

GeneDx Holdings Corp. is a genomics diagnostics company focused on rare disease diagnosis. Its core products are its exome and genome sequencing tests, ExomeDx and GenomeDx.

What is the WGS stock price target?

The Wall Street consensus 12-month price target for WGS is $82.00.